Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Elanco Animal Health (ELAN) stock in plain English

Free brief · no signupStart here
ELANPublished Nov 16, 2026
Elanco Animal Health Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Manufactures medicines, vaccines, and parasite prevention treatments for companion animals and production livestock.
Assets:
Zenrelia canine therapyDermatology treatment with high clinic reorder rates
Credelio parasiticide portfolioBroad-spectrum oral protection against fleas and ticks
Global manufacturing networkProduction facilities across North America, Europe, and Asia
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

49
OPS ScoreOperating finances
Latest quote
-1.54%$26.29
$13.14B
n/a (loss)
$5.15B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ELAN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Elanco Animal Health (ELAN) do?

Elanco Animal Health Inc (ELAN) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Manufactures medicines, vaccines, and parasite prevention treatments for companion animals and production livestock. The company develops and manufactures prescription pharmaceuticals and parasiticides for pets and farm livestock. It is worth $13.14B on the market and sold $5.15B over the last year.

Market cap
$13.14B
P/E ratio
None (reported a loss)
Annual sales
$5.15B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 16, 2026

Brands and businesses behind ELAN

  • Seresto: Provides long-lasting flea and tick prevention collars for dogs and cats through retail stores and veterinary clinics.
  • Credelio: Protects dogs and cats from fleas and ticks using monthly chewable tablets prescribed by veterinarians.
  • Zenrelia: Controls canine allergic itch and atopic dermatitis through daily oral tablets sold to veterinary practices.
  • Galliprant: Relieves canine osteoarthritis pain and stiffness with daily prescription tablets sold through veterinary clinics.
  • Advantage: Delivers topical flea prevention treatments for dogs and cats sold through retail pet channels and clinics.
  • Rumensin: Increases feed efficiency and controls disease in commercial cattle herds through medicated feed additives.

ELAN’s flags, in plain English

Each flag is a number from Elanco Animal Health’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Stupid Cash

Can pay this year's bills 2.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 56% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 45.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -2.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

Questions about ELAN

How big is Elanco Animal Health?

Elanco Animal Health’s market cap is $13.14B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $5.15B: what customers paid the company over the last year, before any costs.

What is ELAN’s P/E ratio?

ELAN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with ELAN?

High debt levels from past acquisitions restrict operational flexibility and increase ongoing interest expenses. That is one risk on Elanco Animal Health’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Elanco Animal Health’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ELAN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card